The FDA approved Eli Lilly’s Alzheimer’s treatment, donanemab, under the brand name Kisunla, making it the second drug in the U.S. market aimed at slowing the progression of the disease. It will compete with Eisai and Biogen’s Leqembi. Both treatments are monoclonal antibodies designed to clear amyloid in the brain. Despite facing regulatory hurdles, Kisunla’s approval came after a panel of advisers unanimously backed the treatment. The drug was expected to be approved earlier this year, but the FDA convened a panel to weigh the risks and benefits. Kisunla’s approval provides another option for patients with Alzheimer’s.
Source link
Early Alzheimer’s drug developed by Eli Lilly approved by FDA
